Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002334 · ClinicalTrials.gov registry record · Phase 3
A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00002334: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00002334 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 3,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002334, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
Interventions
- DRUG Zidovudine
- DRUG Saquinavir
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Phase | Phase 3 |
What the finished NCT00002334 record still lists
NCT00002334 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher).
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002334 about?
NCT00002334 is a clinical study titled "A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment". To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
What is the current status of trial NCT00002334?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants.
What interventions are being tested in trial NCT00002334?
The interventions under investigation include: Zidovudine (DRUG), Saquinavir (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00002334?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002334's enrollment target sits among peer trials
3,000 79th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial